Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Ms. Amy Trombly es el Chief Executive Officer de Sonoma Pharmaceuticals Inc, se unió a la empresa desde 2019.
¿Qué tal es el rendimiento del precio de la acción SNOA?
El precio actual de SNOA es de $1.08, ha disminuido un 2.7% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Sonoma Pharmaceuticals Inc?
Sonoma Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Sonoma Pharmaceuticals Inc?
La capitalización bursátil actual de Sonoma Pharmaceuticals Inc es $1.8M
¿Es Sonoma Pharmaceuticals Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Sonoma Pharmaceuticals Inc, incluyendo 3 fuerte compra, 3 compra, 1 mantener, 0 venta, y 3 fuerte venta